Thermal Sensitive Liposomes Improve Delivery of Boronated Agents for Boron Neutron Capture Therapy

被引：31

作者：

Luderer, Micah John ^{[1
]}

Muz, Barbara ^{[1
]}

Alhallak, Kinan ^{[1
,2
]}

Sun, Jennifer ^{[1
,2
]}

Wasden, Katherine ^{[1
]}

Guenthner, Nicole ^{[1
]}

de la Puente, Pilar ^{[1
]}

Federico, Cinzia ^{[1
]}

Azab, Abdel Kareem ^{[1
,2
]}

机构：

[1] Washington Univ, Sch Med, Canc Biol Div, Dept Radiat Oncol, 4511 Forest Pk Ave,Room 3103, St Louis, MO 63108 USA

[2] Washington Univ, Dept Biomed Engn, St Louis, MO 63110 USA

来源：

PHARMACEUTICAL RESEARCH | 2019年 / 36卷 / 10期

基金：

美国国家卫生研究院;

关键词：

boron neutron capture therapy; boronated compound; glioma; drug delivery; thermal sensitive liposomes; BORONOPHENYLALANINE-FRUCTOSE; DOXORUBICIN RELEASE; DRUG-DELIVERY; HYPERTHERMIA; STABILITY; HYPOXIA; BPA;

D O I：

10.1007/s11095-019-2670-z

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

Purpose Boron neutron capture therapy (BNCT) has the potential to become a viable cancer treatment modality, but its clinical translation requires sufficient tumor boron delivery while minimizing nonspecific accumulation. Methods Thermal sensitive liposomes (TSLs) were designed to have a stable drug payload at physiological temperatures but engineered to have high permeability under mild hyperthermia. Results We found that TSLs improved the tumor-specific delivery of boronophenylalanine (BPA) and boronated 2-nitroimidazole derivative B-381 in D54 glioma cells. Uniquely, the 2-nitroimidazole moiety extended the tumor retention of boron content compared to BPA. Conclusion This is the first study to show the delivery of boronated compounds using TSLs for BNCT, and these results will provide the basis of future clinical trials using TSLs for BNCT.

引用

页数：8

共 24 条

[1]

Azab AK, 2005, STUD INORG CHEM, V22, P337

[2] Boron neutron capture therapy of cancer: Current status and future prospects [J].